Sustained Response to Eculizumab in a Patient With COVID-19–Associated Acute Thrombotic Microangiopathy of the Allograft Kidney: A Case Report
Transplantation proceedings
; 2023.
Article
in English
| EuropePMC | ID: covidwho-2302426
ABSTRACT
Acute thrombotic microangiopathy (TMA) developing in association with SARS-CoV-2 infection is a rare but recognized phenomenon in native kidneys. In the allograft kidney, a diagnosis of TMA has a broad etiologic differential, including antibody-mediated rejection and recurrent and de novo causes of TMA that affect the native kidney. Prior case reports have described plasma exchange or eculizumab use in patients with COVID-19–associated TMA. Herein, we describe the course of a kidney transplant patient with COVID-19–associated TMA with response to eculizumab that was sustained after medication withdrawal and review the literature on COVID-19–associated TMA of the allograft kidney.
Search on Google
Collection:
Databases of international organizations
Database:
EuropePMC
Type of study:
Case report
Language:
English
Journal:
Transplantation proceedings
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS